APA (7th ed.) Citation

Landry, I., Nakai, K., Ferry, J., Aluri, J., Hall, N., Lalovic, B., & Moline, M. L. (2021). Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults. Clinical pharmacology in drug development, 10(2), 153-165. https://doi.org/10.1002/cpdd.817

Chicago Style (17th ed.) Citation

Landry, Ishani, Kenya Nakai, Jim Ferry, Jagadeesh Aluri, Nancy Hall, Bojan Lalovic, and Margaret L. Moline. "Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults." Clinical Pharmacology in Drug Development 10, no. 2 (2021): 153-165. https://doi.org/10.1002/cpdd.817.

MLA (9th ed.) Citation

Landry, Ishani, et al. "Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults." Clinical Pharmacology in Drug Development, vol. 10, no. 2, 2021, pp. 153-165, https://doi.org/10.1002/cpdd.817.